# Cencora (COR) Q3 FY2026 earnings

Results filed 2026-08-05 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/cor/2026-q3/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1140859/000114085926000032/0001140859-26-000032-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Cencora closed its OneOncology acquisition in February 2026, deepening its specialty and oncology reach while GLP-1 volume and an oncology customer loss reshape U.S. demand.

Cencora completed the February 2026 acquisition of OneOncology, adding oncology practice relationships to its specialty business. U.S. demand grew on unit volume, including specialty products sold to health systems and physician practices and GLP-1 products for diabetes and weight loss. Offsetting this were lower brand manufacturer prices, the 2025 loss of an oncology customer and lower sales to its large mail order customer. In April 2026 it divested U.S. Consulting Services.
Management is steering toward a pharmaceutical-centric strategy built on specialty, digital transformation and talent, while exploring strategic alternatives for MWI Animal Health, Profarma and parts of PharmaLex. The tension is mix: GLP-1s carry lower gross margins, and the acquisition was financed with senior notes and term loans, raising interest costs. A new CFO and Chief Human Resources Officer have also joined the leadership team.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Revenue | $84.8 billion | up 5.1% from a year ago | GAAP |
| Diluted EPS | $3.94 | up from $3.52 a year ago | GAAP |
| Adjusted diluted EPS | $4.48 | up 12.0% from $4.00 | non-GAAP |
| Net income attributable to Cencora | $764M |  | GAAP |
| Operating income | $1.1B | up 29.1% from a year ago | GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| U.S. Healthcare Solutions revenue | $74.9 billion | up 4.9% |
| International Healthcare Solutions revenue | $7.7 billion | up 5.9% |
| Other revenue | $2.3 billion | up 6.9% |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Adjusted diluted EPS | fiscal 2026 | $17.75 to $17.95 |
| Revenue growth | fiscal 2026 | 4% to 6% growth |
| Adjusted operating income growth | fiscal 2026 | 13% to 14% growth |
| Adjusted effective tax rate | fiscal 2026 | ~20% |
| Capital expenditures | fiscal 2026 | ~$900M |

## Key takeaways

1. **OneOncology deal deepens oncology and specialty reach** The February 2026 acquisition lifted U.S. gross margin and added operating expenses. It extends Cencora's specialty position with physician practices.
2. **Specialty and GLP-1 volume drive U.S. demand** U.S. growth came largely from unit volume, including specialty products to health systems and physician practices and GLP-1 products. GLP-1s carry lower gross profit margins.
3. **Customer losses are a partial drag** The 2025 loss of an oncology customer and lower sales to the large mail order customer offset growth, as expected and consistent with the second quarter.
4. **Portfolio pruning continues with divestiture and reviews** U.S. Consulting Services was divested in April 2026, and MWI Animal Health, Profarma and parts of PharmaLex are under strategic alternatives review.
5. **Buyback pulled forward; guidance raised** Cencora repurchased $1 billion of shares, the amount it had expected to complete by end of calendar 2026, and raised its adjusted EPS range.

## Questions

**What did Cencora acquire and how did it affect the quarter?** Cencora acquired OneOncology in February 2026, which raised U.S. Healthcare Solutions gross margin and operating expenses and was financed partly with senior notes and term loans.
**What is driving U.S. demand?** Unit volume growth, including specialty products sold to health systems and physician practices and GLP-1 products for diabetes and weight loss.
**Which customers weighed on U.S. sales?** The 2025 loss of an oncology customer and lower sales to its large mail order customer, partly offset growth.
**What is happening with non-core businesses?** U.S. Consulting Services was divested in April 2026, and MWI Animal Health, Profarma and certain PharmaLex components are being explored for strategic alternatives.
**How did Cencora change its outlook?** It raised adjusted diluted EPS guidance to $17.75 to $17.95 from $17.70 to $17.90 and narrowed adjusted operating income growth to 13% to 14%, after repurchasing $1 billion of shares.

## Slides and investor documents

- [Presentation](https://s203.q4cdn.com/785768684/files/doc_financials/2026/q3/Q3-FY26-Earnings-Presentation-vF.pdf) (Slide deck)
- [Webcast](https://events.q4inc.com/attendee/632369927) (Webcast replay)
- [News Release](https://s203.q4cdn.com/785768684/files/doc_financials/2026/q3/Q3-FY26-Earnings-Press-Release-vF.pdf) (Document)
- [Form 10-Q](https://d18rn0p25nwr6d.cloudfront.net/CIK-0001140859/2d620766-6387-4352-b494-ac9f52c440e1.pdf) (Document)

